Addex Therapeutics (ADXN) EBT (2018 - 2025)

Addex Therapeutics has disclosed EBT across 8 years of filings, most recently posting -$2.3 million for Q4 2025.

• EBT for Q4 2025 came in at -$2.3 million, down 68.91% year-over-year; the trailing twelve-month figure through Dec 2025 was -$8.3 million (down 48.36% YoY), and the FY2025 annual result was -$8.3 million, down 47.27% from the prior year.
• EBT came in at -$2.3 million for Q4 2025 at Addex Therapeutics, down from -$2.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $6.6 million in Q4 2022 to a low of -$7.5 million in Q2 2022.
• The 5-year median for EBT is -$1.9 million (2024), against an average of -$2.2 million.
• Across the five-year window, EBT surged 237.36% in 2022 and sank 177.79% in 2024, its largest moves.
• Addex Therapeutics' EBT stood at -$4.8 million in 2021, then soared by 237.36% to $6.6 million in 2022, then slumped by 115.36% to -$1.0 million in 2023, then sank by 34.16% to -$1.4 million in 2024, then plunged by 68.91% to -$2.3 million in 2025.
• The last three EBT figures came in at -$2.3 million (Q4 2025), -$2.0 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.